Baseline demographics and clinical characteristics
| Patient characteristics . | Cohorts I + III (n = 23) . | Cohort II (n = 2) . | Total (N = 25) . |
|---|---|---|---|
| Age, y | |||
| Median | 66.0 | 64.5 | 66.0 |
| Range | (34-85) | (55-74) | (34-85) |
| Women, n (%) | 11 (47.8) | 0 (0.0) | 11 (44.0) |
| Ann Arbor disease stage, n (%)* | |||
| I and II | 5 (21.7) | 0 (0.0) | 5 (20.0) |
| III and IV | 18 (78.3) | 2 (100.0) | 20 (80.0) |
| High risk by IPI, n (%)* | 5 (21.7) | 0 (0.0) | 5 (20.0) |
| Refractory disease, n (%)† | 15 (65.2) | 1 (50.0) | 16 (64.0) |
| Bulky disease, n (%)‡ | 6 (26.1) | 1 (50.0) | 7 (28.0) |
| No. of lines of prior anti-tumor therapies | |||
| Median | 3 | 2 | 3 |
| Range | (1-7) | (1-4) | (1-7) |
| Prior autologous HSCT, n (%) | 6 (26.1) | 1 (50.0) | 7 (28.0) |
| Months since last anti-tumor treatment | |||
| Median | 1.4 | 5.0 | 1.5 |
| Range | (0.2-73.1) | (1.8-8.2) | (0.2-73.1) |
| Months since last rituximab treatment | |||
| Median | 3.1 | 5.1 | 3.1 |
| Range | (0.8-73.1) | (2.0-8.2) | (0.8-73.1) |
| Transformed disease, n (%)§ | 10 (43.5) | 0 (0.0) | 10 (40.0) |
| Patient characteristics . | Cohorts I + III (n = 23) . | Cohort II (n = 2) . | Total (N = 25) . |
|---|---|---|---|
| Age, y | |||
| Median | 66.0 | 64.5 | 66.0 |
| Range | (34-85) | (55-74) | (34-85) |
| Women, n (%) | 11 (47.8) | 0 (0.0) | 11 (44.0) |
| Ann Arbor disease stage, n (%)* | |||
| I and II | 5 (21.7) | 0 (0.0) | 5 (20.0) |
| III and IV | 18 (78.3) | 2 (100.0) | 20 (80.0) |
| High risk by IPI, n (%)* | 5 (21.7) | 0 (0.0) | 5 (20.0) |
| Refractory disease, n (%)† | 15 (65.2) | 1 (50.0) | 16 (64.0) |
| Bulky disease, n (%)‡ | 6 (26.1) | 1 (50.0) | 7 (28.0) |
| No. of lines of prior anti-tumor therapies | |||
| Median | 3 | 2 | 3 |
| Range | (1-7) | (1-4) | (1-7) |
| Prior autologous HSCT, n (%) | 6 (26.1) | 1 (50.0) | 7 (28.0) |
| Months since last anti-tumor treatment | |||
| Median | 1.4 | 5.0 | 1.5 |
| Range | (0.2-73.1) | (1.8-8.2) | (0.2-73.1) |
| Months since last rituximab treatment | |||
| Median | 3.1 | 5.1 | 3.1 |
| Range | (0.8-73.1) | (2.0-8.2) | (0.8-73.1) |
| Transformed disease, n (%)§ | 10 (43.5) | 0 (0.0) | 10 (40.0) |
IPI, International Prognostic Index.
Stage at most recent assessment (which could be at first diagnosis for some patients).
Refractory to or relapsed within 6 mo of last treatment.
Diameter >7.5 cm.
Patients whose disease transformed from non-DLBCL subtype at the initial assessment to DLBCL and then were r/r after at least 1 regimen for DLBCL.